Logo Logo Logo
  • Who We Are
    • About Adlon
    • Ethics and Compliance
  • Healthcare Professionals
    • Prescribing Responsibly
    • Ask Adlon Medical
    • Products
    • Research
  • Patients & Caregivers
    • Consideration for Use of Prescription Stimulant Medications
    • Storage and Disposal for Prescription Stimulant Medications
    • Ask Adlon Medical
  • Products
    • Adhansia XR
  • Newsroom
    • Press Releases
  • Policies We Support
  • Social Media
  • Contact
    • Ask Adlon Medical
Logo Logo Logo Logo Logo
  • Who We Are
    • About Adlon
    • Ethics and Compliance
  • Healthcare Professionals
    • Prescribing Responsibly
    • Ask Adlon Medical
    • Products
    • Research
  • Patients & Caregivers
    • Consideration for Use of Prescription Stimulant Medications
    • Storage and Disposal for Prescription Stimulant Medications
    • Ask Adlon Medical
  • Products

    • Adhansia XR
  • Newsroom

    • Press Releases
  • Policies We Support
  • Social Media
  • Contact
    • Ask Adlon Medical

Adhansia XR™ (methylphenidate HCl) Extended Release Capsules CII, New ADHD Treatment from Adlon Therapeutics L.P., Now Available Throughout the U.S.

Christian Mazzi, MD, BSBA/BA, MBA Named President and Executive Medical Director, Adlon Therapeutics L.P.

Adlon Therapeutics L.P. Joins the Prescription Drug Safety Network

Adlon Therapeutics L.P. To Provide Funding Opportunities for Research to Expand Understanding of ADHD

Adlon Therapeutics L.P. Announces FDA Approval for Adhansia XR™ (Methylphenidate HCL) Extended-release Capsules CII for the Treatment of ADHD

Privacy Policy
Terms & Conditions
Ethics & Compliance
Do Not Sell My Information
Adlon Therapeutics logo
© Adlon Therapeutics L.P. All Rights Reserved. Adlon Therapeutics L.P. is a subsidiary of Purdue Pharma L.P.